Published in Am J Obstet Gynecol on February 01, 2005
Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev (2012) 4.07
Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin Infect Dis (2012) 2.13
Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis (2011) 1.87
Patterns of Hydrocephalus Caused by Congenital Toxoplasma gondii Infection Associate With Parasite Genetics. Clin Infect Dis (2015) 1.47
Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz (2009) 1.45
Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol (2011) 1.28
Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis (2011) 1.09
Anti-Toxoplasma antibody prevalence, primary infection rate, and risk factors in a study of toxoplasmosis in 4,466 pregnant women in Japan. Clin Vaccine Immunol (2011) 1.08
Serological prevalence of Toxoplasma gondii antibodies in pregnant women from Southern Brazil. Parasitol Res (2010) 0.97
Paediatricians' attitudes and practices towards HPV vaccination. Acta Paediatr (2008) 0.92
Congenital Toxoplasmosis. J Pediatric Infect Dis Soc (2014) 0.92
Congenital toxoplasmosis and prenatal care state programs. BMC Infect Dis (2014) 0.91
Risk factors for ocular toxoplasmosis in Brazil. Epidemiol Infect (2013) 0.88
Drinking water source and human Toxoplasma gondii infection in the United States: a cross-sectional analysis of NHANES data. BMC Public Health (2014) 0.83
Toxoplasmosis during pregnancy: a case report and review of the literature. Hippokratia (2008) 0.81
Establishment and application of a loop-mediated isothermal amplification method for simple, specific, sensitive and rapid detection of Toxoplasma gondii. J Vet Med Sci (2013) 0.81
Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Sci Med (Porto Alegre) (2010) 0.79
Congenital Toxoplasmosis in France and the United States: One Parasite, Two Diverging Approaches. PLoS Negl Trop Dis (2017) 0.77
Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach. J Comput Aided Mol Des (2011) 0.76
Help in the Choice of Automated or Semiautomated Immunoassays for Serological Diagnosis of Toxoplasmosis: Evaluation of Nine Immunoassays by the French National Reference Center for Toxoplasmosis. J Clin Microbiol (2016) 0.75
Seroprevalence and determinants of toxoplasmosis in pregnant women attending antenatal clinic at the university teaching hospital, Lusaka, Zambia. BMC Infect Dis (2017) 0.75
Toxoplasmosis and Toxocariasis: An Assessment of Human Immunodeficiency Virus Comorbidity and Health-Care Costs in Canada. Am J Trop Med Hyg (2016) 0.75
Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: implications for prenatal management and screening. Am J Obstet Gynecol (2006) 0.75
Risk factors for congenital toxoplasmosis are not always obvious. Am J Obstet Gynecol (2006) 0.75
Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis (2015) 0.75
DNA Amplification Techniques for the Detection of Toxoplasma gondii Tissue Cysts in Meat Producing Animals: A Narrative Review Article. Iran J Parasitol (2017) 0.75
Toxoplasma gondii infection in meat animals from Africa: Systematic review and meta-analysis of sero-epidemiological studies. Vet World (2017) 0.75
Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving. PLoS Negl Trop Dis (2017) 0.75
Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis (2006) 2.63
Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin Infect Dis (2012) 2.13
Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis (2011) 1.87
Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine (2010) 1.61
Toxoplasma gondii tachyzoite-bradyzoite interconversion. Trends Parasitol (2002) 1.58
NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect Immun (2010) 1.46
Evolutionary origins of the eukaryotic shikimate pathway: gene fusions, horizontal gene transfer, and endosymbiotic replacements. Eukaryot Cell (2006) 1.44
Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation (2008) 1.41
P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages. J Immunol (2010) 1.33
Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One (2008) 1.32
Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol (2008) 1.30
Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol (2011) 1.28
The shikimate pathway and its branches in apicomplexan parasites. J Infect Dis (2002) 1.25
Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J (2011) 1.25
Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother (2003) 1.17
Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm (2011) 1.13
Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis (2008) 1.10
Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics (2006) 1.10
Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis (2011) 1.09
Expression, purification and crystallization of the Plasmodium falciparum enoyl reductase. Acta Crystallogr D Biol Crystallogr (2003) 1.09
Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology (2007) 1.09
Velo-cardio-facial syndrome. Curr Opin Pediatr (2005) 1.08
Temporal lobe anatomy and psychiatric symptoms in velocardiofacial syndrome (22q11.2 deletion syndrome). J Am Acad Child Adolesc Psychiatry (2006) 1.08
Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrob Agents Chemother (2012) 1.07
Genetic analysis of influences on survival following Toxoplasma gondii infection. Int J Parasitol (2002) 1.04
Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine (2010) 1.04
Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. Pediatr Infect Dis J (2006) 1.03
A conversation with Paul Meier. Interview by Harry M Marks. Clin Trials (2004) 1.03
Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality. Parasitology (2011) 1.02
Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol (2008) 1.00
Lipidomic analysis of Toxoplasma gondii reveals unusual polar lipids. Biochemistry (2007) 1.00
Cataracts in congenital toxoplasmosis. J AAPOS (2007) 0.98
Components of the systemic fetal inflammatory response syndrome as predictors of impaired neurologic outcomes in children. Am J Obstet Gynecol (2003) 0.98
Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents. Acta Crystallogr D Biol Crystallogr (2007) 0.98
In vitro correlates of Ld-restricted resistance to toxoplasmic encephalitis and their critical dependence on parasite strain. J Immunol (2002) 0.97
T. gondii RP promoters & knockdown reveal molecular pathways associated with proliferation and cell-cycle arrest. PLoS One (2010) 0.96
Sex differences in cognitive functioning in velocardiofacial syndrome (VCFS). Dev Neuropsychol (2005) 0.95
Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential anti-microbial agent target. Int J Parasitol (2004) 0.95
Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci U S A (2012) 0.95
Host genetic and epigenetic factors in toxoplasmosis. Mem Inst Oswaldo Cruz (2009) 0.95
Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med (2013) 0.95
Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice. Hum Immunol (2011) 0.94
The unusual mitochondrial compartment of Cryptosporidium parvum. Trends Parasitol (2005) 0.93
Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother (2005) 0.92
22q11.2 deletion syndrome: genetics, neuroanatomy and cognitive/behavioral features keywords. Child Neuropsychol (2005) 0.90
Salicylanilide inhibitors of Toxoplasma gondii. J Med Chem (2012) 0.87
Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase. Bioorg Med Chem Lett (2013) 0.84
Immunogenetics of Toxoplasma gondii informs vaccine design. Trends Parasitol (2010) 0.84
Subcellular localization and dynamics of a digalactolipid-like epitope in Toxoplasma gondii. J Lipid Res (2008) 0.84
Expression, purification and preliminary crystallographic analysis of the Toxoplasma gondii enoyl reductase. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 0.83
Impaired innate immunity in mice deficient in interleukin-1 receptor-associated kinase 4 leads to defective type 1 T cell responses, B cell expansion, and enhanced susceptibility to infection with Toxoplasma gondii. Infect Immun (2012) 0.83
Associations between performance on the Rey-Osterrieth Complex Figure and regional brain volumes in children with and without velocardiofacial syndrome. Dev Neuropsychol (2008) 0.83
Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother (2013) 0.82
Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania. J Med Chem (2012) 0.80
Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Sci Med (Porto Alegre) (2010) 0.79
Current perspectives on Down syndrome: selected medical and social issues. Am J Med Genet C Semin Med Genet (2006) 0.78
Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry (2013) 0.77
Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii. ChemMedChem (2013) 0.77
Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach. J Comput Aided Mol Des (2011) 0.76
Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides. Bioorg Med Chem Lett (2013) 0.76
Identification of isolated lenticulostriate vasculopathy in preterm infants. J Perinatol (2004) 0.75
Spinal Cord Lesions in Congenital Toxoplasmosis Demonstrated with Neuroimaging, Including Their Successful Treatment in an Adult. J Neuroparasitology (2012) 0.75